Table 3 Results from linear regression analysis with EDE-Q at two-year follow-up as outcome variable, for each baseline characteristic between ACT and TAU, while controlling for other characteristics
EDE-Q at T4 between ACT and TAU stratified by | B (95% CI) | SE | p |
|---|---|---|---|
AN spectrum | − 0.856 (− 1.721 to .010) | 0.423 | .052 |
BN spectrum | − 0.515 (− 1.526 to .496) | 0.494 | .306 |
Age < 25 at inclusion | − 1.364 (− 2.268 to − .461) | 0.440 | .005 |
Age ≥ 25 at inclusion | − 0.379 (− 1.371 to .612) | 0.486 | .441 |
Treatment duration < 12 months | − 0.959 (− 1.833 to − .085) | 0.431 | .032 |
Treatment duration ≥ 12 months | − 0.624 (− 1.628 to .381) | 0.483 | .211 |
MADRS-S < 20 | − 0.884 (− 1.705 to − .063) | 0.406 | .036 |
MADRS-S ≥ 20 | − 0.560 (− 1.904 to .784) | 0.642 | .394 |
EDE-Q T1 < 2.76 | − 0.803 (− 1.804 to .197) | 0.472 | .108 |
EDE-Q T1 ≥ 2.76 | − 0.612 (− 1.507 to .282) | 0.443 | .174 |